FDA: Gardasil approved to prevent anal cancer – The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years.
Many clinicians may be screening for cervical cancer too frequently — Many physicians reported overscreening women by using both the HPV and Pap tests annually. – Many physicians reported overscreening women by using both the HPV and Pap tests annually. Clinical guidelines recommend screening low-risk women for cervical cancer every three years after age 30.
Benefit of HPV Vaccination, Frequent Screening for Women over 41 is Likely to be Low – The overall potential benefits of human papillomavirus (HPV) vaccinations or frequent HPV screenings for women over the age of 41 are low, concludes a new study published online February 15 in the Journal of the National Cancer Institute.
First Cervical Cancer Screening Delayed Until Age 21 — Less Frequent Pap Tests Recommended. – Women should have their first cervical cancer screening at age 21 and can be rescreened less frequently than previously recommended, reported by US researchers at ACOG.
FDA-approved drugs fulvestrant and raloxifene eliminate, prevent cervical cancer in mice. – Researchers eliminated cervical cancer in mice with two FDA-approved drugs currently used to treat breast cancer and osteoporosis. The study is published in the Proceedings of the National Academy of Sciences.
Study: Benefit to women not enough to sway men to get HPV vaccine – Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.
GARDASIL? is First Cervical Cancer Vaccine to Receive WHO Pre-qualification — WHO Pre-qualification Will Help to Facilitate Expanded Global Access and Implementation of HPV Vaccination Programs. – GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck’s cervical cancer vaccine, has been awarded World Health Organization (WHO) pre-qualification. GARDASIL is the first cervical cancer vaccine to receive WHO pre-qualification.
Studies of GARDASIL, Merck’s Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference – In a study of an extended follow up of 290 women na?ve to HPV type 16, the HPV 16 component of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] was efficacious against HPV 16 infection for an average of 8.5 years after administration.
QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata, India. – QIAGEN and the Chittaranjan National Cancer Institute (CNCI) announced a collaboration to establish the first large-scale cervical cancer screening program for women in Kolkata, India.
New Local TV Ad Campaign To Educate Memphis Women About Cervical Cancer Prevention and HPV Testing – Through a new advertising campaign being launched in US, local women will soon learn more about cervical cancer screening and prevention.
Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL? in Women Ages 27 through 45 – Merck & Co., Inc. announced that the U.S. Food and Drug Administration has issued a second complete response letter regarding the supplemental biologics license application (sBLA) for the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] in women ages 27 though 45.
GARDASIL?, Merck’s Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study. – GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV) types 6, 11, 16 and 18 in a pivotal Phase III study in men aged 16 to 26.
